Hosted on MSN3d
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Hosted on MSN13d
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority TagMerck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral ...
MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.
The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.
Merck MRK-0.87%decrease; red down pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...
On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...
For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback